Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group a, c, w-135 and y conjugate vaccine (Sanofi, 0435ac)
- Development stage
- Unknown
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MenQuadfi is a quadrivalent conjugate vaccine developed by Sanofi Pasteur for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, W-135, and Y. The vaccine contains capsular polysaccharides from each of the four serogroups, individually conjugated to a tetanus toxoid protein carrier. This conjugation enhances the immune response by engaging T-cells, leading to higher antibody titers and the induction of immunological memory, which is particularly important for infants and young children. MenQuadfi was approved by the U.S. FDA in 2020 for use in individuals 6 weeks of age and older and is administered as a single intramuscular injection. It does not provide protection against serogroup B meningococcal disease.
- Brand names
- MenQuadfi
- Other names
- meningococcal polysaccharide group A, C, W-135 and Y conjugate vaccineQuadrivalent meningococcal conjugate vaccine
02
Targets
CD4+ T-cell receptor (TCR) recognizing tetanus toxoid-derived peptidesNmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal group a, c, w-135 and y conjugate vaccine (Sanofi, 0435ac).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group a, c, w-135 and y conjugate vaccine (Sanofi, 0435ac).